Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Brainstorm Cell Therapeutics Inc. BCLI

Healthcare  —  Biotechnology
0.97 0.02 2.11% as of 25 Sep
Market cap
$7.0M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Brainstorm Cell Therapeutics Inc. (BCLI) Business Profile

Updated before January 2025

Company Overview

Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology company dedicated to the development of innovative cellular therapies for neurodegenerative diseases. Founded in 2004, the company is headquartered in New York City, USA, with additional operations in Petach Tikva, Israel. BCLI was established with the mission to harness the potential of adult stem cells to address unmet medical needs in the field of neurology. The company’s leadership team includes highly experienced professionals in biotechnology and healthcare, with Chaim Lebovits serving as the President and CEO. Under his guidance, BCLI has made significant strides in advancing its proprietary technologies and clinical programs.

Core Business Segments

BCLI focuses on the development and commercialization of autologous cellular therapies. Its primary product candidate is NurOwn®, a proprietary platform technology designed to treat neurodegenerative diseases by utilizing mesenchymal stem cells (MSCs) derived from the patient’s own bone marrow. These MSCs are engineered to secrete neurotrophic factors (NTFs), which promote the survival and growth of neurons.

Key Products and Services

  1. NurOwn®: The company’s flagship product, NurOwn®, is currently being developed for the treatment of Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and other neurodegenerative conditions. NurOwn® has shown promise in clinical trials by improving functional outcomes and slowing disease progression.

  2. Pipeline Development: In addition to ALS and MS, BCLI is exploring the potential of its technology platform for other indications, including Alzheimer’s disease and Parkinson’s disease. The company is actively engaged in preclinical and early-stage clinical studies to expand its therapeutic portfolio.

  3. Collaborative Research: BCLI collaborates with leading academic institutions and research organizations to advance its understanding of neurodegenerative diseases and refine its therapeutic approaches.

Business Model

BCLI operates on a research-driven business model that integrates cutting-edge science with patient-centric solutions. The company generates revenue through licensing agreements, partnerships, and potential future commercialization of its therapies. By leveraging its proprietary NurOwn® technology, BCLI aims to establish itself as a leader in the field of regenerative medicine. The company’s approach involves:

  • Conducting rigorous clinical trials to demonstrate the safety and efficacy of its therapies.
  • Partnering with pharmaceutical companies and healthcare providers to facilitate the distribution and adoption of its products.
  • Investing in research and development to expand its pipeline and address additional therapeutic areas.

Strategic Direction

BCLI’s strategic priorities include:

  1. Advancing Clinical Programs: The company is focused on completing late-stage clinical trials for NurOwn® in ALS and initiating new trials for other indications.

  2. Regulatory Approvals: BCLI is actively working with regulatory agencies, including the FDA and EMA, to secure approvals for its therapies.

  3. Global Expansion: The company aims to expand its presence in international markets by establishing partnerships and collaborations.

  4. Sustainability Goals: BCLI is committed to ethical and sustainable practices in its research, development, and manufacturing processes.

  5. Innovation: The company continues to invest in cutting-edge technologies to enhance the efficacy and scalability of its therapies.

Competitive Landscape

BCLI operates in a highly competitive biotechnology sector, where it faces competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Biogen Inc.: A leader in neurology-focused therapies, Biogen develops treatments for ALS and other neurodegenerative diseases.
  • Novartis AG: Known for its innovative therapies, Novartis is actively involved in the development of regenerative medicine.
  • Sangamo Therapeutics: Specializes in gene therapy and cell therapy for neurological disorders.
  • Bluebird Bio: Focuses on gene and cell therapies for rare diseases, including neurodegenerative conditions.

Despite the competition, BCLI differentiates itself through its proprietary NurOwn® technology and patient-centric approach.

Risk Factors

BCLI faces several risks that could impact its operations and financial performance:

  1. Regulatory Challenges: Obtaining regulatory approvals for new therapies is a complex and time-consuming process.
  2. Market Dependence: The company’s success is heavily reliant on the commercialization of NurOwn®.
  3. Supply Chain Disruptions: Any disruptions in the supply chain for raw materials or manufacturing processes could delay product development.
  4. Competition: Intense competition in the biotechnology sector may limit BCLI’s market share.
  5. Financial Risks: As a development-stage company, BCLI may face challenges in securing sufficient funding to support its operations.

Recent Developments

In recent years, BCLI has achieved several milestones:

  • Clinical Trial Progress: The company completed a Phase 3 clinical trial for NurOwn® in ALS, with results demonstrating potential benefits for certain patient subgroups.
  • Regulatory Engagement: BCLI submitted a Biologics License Application (BLA) to the FDA for NurOwn® and is awaiting feedback.
  • Partnerships: The company entered into collaborations with leading research institutions to advance its pipeline.
  • COVID-19 Impact: While the pandemic posed challenges, BCLI adapted by implementing remote work policies and ensuring continuity in its clinical programs.

Investment Considerations

Strengths

  • Innovative Technology: BCLI’s NurOwn® platform represents a novel approach to treating neurodegenerative diseases.
  • Strong Pipeline: The company has a robust pipeline with potential applications in multiple therapeutic areas.
  • Experienced Leadership: BCLI’s management team has a proven track record in biotechnology and healthcare.
  • Collaborative Approach: Partnerships with academic institutions and research organizations enhance the company’s capabilities.

Risks

  • Regulatory Uncertainty: Delays or rejections in regulatory approvals could impact the company’s growth.
  • Financial Dependence: BCLI relies on external funding to support its operations and clinical programs.
  • Market Competition: The biotechnology sector is highly competitive, with numerous players vying for market share.

Conclusion

Brainstorm Cell Therapeutics Inc. is at the forefront of developing innovative cellular therapies for neurodegenerative diseases. With its proprietary NurOwn® technology, the company has the potential to address significant unmet medical needs. While challenges remain, including regulatory and financial risks, BCLI’s strong pipeline, experienced leadership, and collaborative approach position it for long-term success. As the company advances its clinical programs and explores new therapeutic areas, it is well-positioned to make a meaningful impact in the field of regenerative medicine.